GPX4 and cancer: For example, Luo et al. developed the PROTAC dGPX4 to target GPX4 and showed in vivo that it potently induces ferroptosis selectively in cancer cells with no apparent side effects,333 providing a promising novel strategy for the development of clinically applicable GPX4-targeted drugs.